To improve tumor tissue penetration and thus therapeutic efficacy, we developed a novel type of ADCs composed of anti-HER2 scFv–HSA fusion antibodies conjugated with the potent cytotoxic drug DM1 for HER2-positive cancer therapy. Here, ALB is linked to cancer.